ReachRxResearch
Home
Research
Sign Up
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Back to Research Hub
  1. Home
  2. Research Hub
  3. On-demand transarterial chemoembolisatio…

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

The Lancet Gastroenterology & Hepatology·August 25
Gastroenterology & HepatologyConfirms priorHepatocellular CarcinomaRandomized Controlled TrialAnti-VEGF AntibodyPD-L1 InhibitorTransarterial ChemoembolisationAdultAvastinTecentriqAtezolizumabBevacizumab

Summary

View source

What was studied

This phase 3 RCT (TALENTACE) evaluated on-demand TACE plus atezolizumab (1200 mg IV) and bevacizumab (15 mg/kg IV) every 3 weeks versus on-demand TACE alone in 342 patients with untreated, intermediate-to-high tumour burden unresectable HCC (six-and-twelve score ≥6) across 40 centres in China and Japan, with a median follow-up of 26.25 months.

Key findings

Adding atezolizumab + bevacizumab to on-demand TACE significantly improved TACE-PFS: median 11.30 months vs. 7.03 months (HR 0.71, 95% CI 0.55–0.92; p=0.0089). Overall survival remained immature at the first interim analysis (median ~34.5 vs. ~35.4 months; HR 0.96, 99.62% CI 0.58–1.58), with no significant difference yet observed.

Study limitations

- Overall survival data are immature and no OS benefit has been demonstrated at this interim analysis. - Trial was conducted exclusively in China and Japan (90% Chinese), limiting generalisability to Western populations. - Open-label design introduces potential performance and assessment bias.

Clinical implications

For patients with intermediate-to-high tumour burden unresectable HCC, combining on-demand TACE with atezolizumab + bevacizumab meaningfully delays untreatable progression compared to TACE alone. However, an OS benefit has not yet been confirmed—clinicians should weigh the improved TACE-PFS against the added toxicity burden (notably hypertension 14%, thrombocytopenia 14%, and 5 treatment-related deaths) while awaiting mature OS data.

Caveats

  • Overall survival data are immature at this publication; the OS result (HR 0.96) should be interpreted cautiously and not used as a primary efficacy conclusion.
  • TACE-PFS is a surrogate endpoint specific to this trial; it is not a universally standardised oncology endpoint, which may complicate cross-trial comparisons.
  • The brand name 'Tecentriq' is used for atezolizumab; availability and labelling may vary by region.
Show all 4
  • The trial enrolled almost exclusively Asian patients (90% Chinese, 10% Japanese), which may limit applicability to non-Asian populations.

Related Questions

Explore related topics

What is the evidence for combining TACE with immunotherapy in intermediate-stage hepatocellular carcinoma?How does atezolizumab plus bevacizumab compare to sorafenib or lenvatinib as first-line therapy in advanced HCC?What are the safety considerations for bevacizumab combined with TACE in liver cancer patients?

Publication Details

Year
2026
Journal
The Lancet Gastroenterology & Hepatology
Sample Size
n=342
Source
View article
Keep scrolling
More content below.
Up Next